Antibody-drug Conjugates

Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

by
Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

Due to the differences in selecting target antigens, effective payloads, linkers, and conjugation methods for antibody-drug conjugates (ADCs), there is structural diversity and complexity. Moreover, ADCs cannot simply be equated to a combination of antibody drugs and effective payloads, as there are numerous challenges in clinical development, including the complexity of pharmacokinetics, insufficient tumor targeting, … Read more

ADC Overview: The Technical Landscape of ‘Biological Missiles’

by
ADC Overview: The Technical Landscape of 'Biological Missiles'

🔬 Introduction From Paul Ehrlich’s concept of the “magic bullet” in the early 20th century to the approval of the first ADC drug Mylotarg in 2000, antibody-drug conjugates (ADCs) have undergone a century of evolution and have become a “star therapy” in the field of precision oncology. This “biological missile,” which combines the targeting ability … Read more

Comprehensive Analysis of ADC Conjugation Technology

by
Comprehensive Analysis of ADC Conjugation Technology

Abstract: Antibody-drug conjugates (ADCs), known as “precision missiles” for cancer treatment, can accurately target tumor cells without harming normal tissues. The core of this technology lies inconjugation technology— the method of linking cytotoxic drugs (the warhead) with antibodies (the navigation system). This article starts from the working principle of ADCs, breaking down three major categories … Read more

After ADC, the ‘Bottlebrush’ ABC Has Arrived!

by
After ADC, the 'Bottlebrush' ABC Has Arrived!

“Structure similar to a bottlebrush” In recent years, antibody-drug conjugates (ADCs) have emerged as a novel targeted therapy strategy, achieving precise targeting of cancer cells by covalently linking monoclonal antibodies with small molecule drugs. They have demonstrated good efficacy and safety in the treatment of various cancers. However, traditional ADCs still face many limitations in … Read more

The ‘Frenzied Growth’ of ADC Drugs is Not the Precision Missile You Imagine

by
The 'Frenzied Growth' of ADC Drugs is Not the Precision Missile You Imagine

Antibody-Drug Conjugates (ADCs) are considered the “star” drugs in the field of tumor therapy and are currently experiencing explosive growth. To date, 17 ADCs have received regulatory approval, with 13 approved by the U.S. Food and Drug Administration (FDA), and over 300 ADCs are in clinical development. These drugs are often likened to “precision missiles,” … Read more

Antibody-Drug Conjugates in Cancer Therapy: Innovations, Challenges, and Future Directions

by
Antibody-Drug Conjugates in Cancer Therapy: Innovations, Challenges, and Future Directions

Antibody-drug conjugates (ADCs) have emerged as a promising approach for cancer treatment, garnering significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, they enhance the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. However, several challenges remain: including the selection of appropriate target antigens, enhancing antibodies, … Read more

Unveiling the Potential of Antibody-Drug Conjugates

by
Unveiling the Potential of Antibody-Drug Conjugates

This article, “Unveiling the Potential of Antibody-Drug Conjugates,” is an excellent industry review that provides a panoramic view of the hot field of Antibody-Drug Conjugates (ADCs). Next, we will journey from history to the future, delving into molecular mechanisms and clinical practices, connecting textbook knowledge to cutting-edge research. A Precision Guided “Trojan Horse”: An In-Depth … Read more

Review Considerations for Antibody-Drug Conjugates (ADC) Pharmaceutical Research

by
Review Considerations for Antibody-Drug Conjugates (ADC) Pharmaceutical Research

This page’s PPT lacks a guiding principle, which is as follows: four guiding principles: Article information source from the WeChat public account Pharmacology Talk *This WeChat public account maintains neutrality regarding all original and reprinted content, statements, and opinions. The content is for public sharing only. If any reprinted works or images have incorrect author … Read more

ADC: Where It Comes From and Where It Is Going?

by
ADC: Where It Comes From and Where It Is Going?

ADC, or antibody-drug conjugates, is a term that everyone is likely familiar with. The design concept of ADC originated from Paul Ehrlich’s idea of “magic bullets,” aimed at achieving precise targeted therapy while minimizing damage to normal tissues. As of now, there are 15 ADC drugs approved for market worldwide, with over 400 ADC candidates … Read more